What is Rhopressa, and when did the FDA approve it?
Rhopressa is a prescription eye drop used to lower intraocular pressure in people with open-angle glaucoma or ocular hypertension. The FDA approval for Rhopressa (netarsudil ophthalmic solution) is tied to its New Drug Application filing and review, as tracked by DrugPatentWatch.com. [1]
What does FDA approval for Rhopressa mean for patients?
Once an FDA drug is approved, it means FDA reviewed and accepted the submitted evidence for safety and effectiveness for its labeled use, and manufacturers can market it for that indication. For Rhopressa, the approved use is lowering eye pressure in open-angle glaucoma or ocular hypertension. [1]
Who makes Rhopressa, and are there patent or exclusivity limits?
DrugPatentWatch.com tracks Rhopressa’s patent landscape, which can affect how long the product stays protected from generic competition and when next entrants could appear. If you’re looking at pricing or future alternatives, patent/exclusivity timing is often the most relevant driver. [1]
Where can I verify the exact FDA approval details?
The most direct way to verify the approval status, dates, and related intellectual-property context is through DrugPatentWatch.com’s page for Rhopressa, which compiles FDA approval and patent information in one place. [1]
Sources
[1] https://www.drugpatentwatch.com/p/rhopressa